Ansun Biopharma names new chief medical officer
9 October 2018 -

Ansun Biopharma Inc, a biotechnology company focused on the development of novel broad spectrum anti-viral biologic therapeutics to combat severe viral infections, announced yesterday that it has named Stanley Lewis, MD, MPH as its new chief medical officer.

Dr Lewis will manage the clinical development of DAS181, Ansun's lead experimental product and a biologic anti-viral therapeutic compound that is positioned to enter a global Phase 3 clinical trial for the treatment of parainfluenza virus infection in hospitalised immunocompromised patients.

Dr Lewis joins the company from TaiMed Biologics, where as chief medical officer, he spent the past ten years leading the development of TROGARZO, a drug for treating multi-drug resistant HIV, from an early stage compound to FDA approval.